...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: New PP on SEDAR

The bulk was from one investor in Hong Kong. That brings a total investment into Zenith to about 3M since the beginning of the year. The latest PP, each unit is 1 share and a half warrant for $1.38. What I found interesting is that the warrants expire this November.

It's a puzzle.  In the Jan 13 PP, Hong Kong appears to be paying 1.3430 per share with half a warrant, expiring 2023-11-14.  Others in that placement were paying as little as 0.8050 per share with two warrants, expiring 2028-01-11.  Unless I missed something, I'm inclined to read that as less than optimal bargaining or awesome salesmanship, rather than good news coming. 

Share
New Message
Please login to post a reply